Chuang Emil 4

What Happened

• Emil Chuang, a director of Palisade Bio, received a grant of 592,300 restricted stock units (RSUs) and had derivative conversions/exercises recorded on June 10, 2026. The filing shows 20,200 shares were acquired via conversion/exercise and an equal 20,200 were disposed at $0.00 (no cash proceeds reported). No dollar values for the RSU grant were reported in the Form 4.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (filed within the normal 2-business-day window).
• Grant: 592,300 RSUs granted (price N/A; contingent right to one share per RSU).
• Conversions/Exercises: 20,200 shares acquired (price N/A) and 20,200 shares disposed at $0.00 (listed as derivative disposition).
• Shares owned after the transactions: not specified in the filing.
• Footnotes of note:
  • F1: The 592,300 RSUs are service‑based and vest in three equal annual installments; first installment vests at the earlier of the 2027 annual meeting or June 10, 2027, subject to continued service.
  • F2: A separate RSU grant vested on June 10, 2026 (supports the conversion/exercise entries).
  • F3: Another RSU grant description notes a three‑year vesting schedule with first vesting tied to the 2026 annual meeting or Oct 6, 2026.
• The filing does not state a 10b5-1 plan or specific reason for the $0.00 disposition.

Context

• RSU grants are awards (not open‑market purchases) and are typically compensation; they do not necessarily signal the insider’s view of the stock’s near‑term prospects.
• The paired acquisition and $0.00 disposition of the same number of shares often reflects net settlement or share withholding to satisfy tax obligations upon vesting/conversion, though the filing does not explicitly state that here.
• This was a director-level compensation/vesting event rather than a routine open‑market buy or sale.